NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions
The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...
Policy / Regulatory
Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth
Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...
Sichuan Health Commission Issues Directive to Strengthen Oversight of External Prescriptions
The Health Commission of Sichuan Province has issued a notification aimed at enhancing the management...
Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development
Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration,...
Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel
The Shanghai medical products administration has released the “Measures for the Management of Key Quality...
Shanghai Enhances Biomedicine IP Protection with New Procurement-Linked Measures
The Shanghai Intellectual Property Administration (SIPA) has issued a notification highlighting the city’s intensified efforts...
China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes
The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...
China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy
The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...
China’s NHSA Unveils Measures to Secure Volume-Based Procurement Supply
The National Healthcare Security Administration (NHSA) has issued a notification outlining key measures to ensure...
China’s NHC Unveils Strategy to Enhance Pediatric Healthcare by 2025
The National Health Commission (NHC) has issued a set of Opinions aimed at “Promoting the...
Corruption Investigations Target Former HSA Officials in Guizhou and Hainan Amid Nationwide Crackdown
Corruption investigations have been launched against former senior officials of the Healthcare Security Administration (HSA)...
China’s NHSA Aims to Balance Drug Prices with New Monitoring System by March 2024
The National Healthcare Security Administration (NHSA) has issued a notification aimed at fostering inter-provincial price...
China’s NMPA Issues Guidelines for Inspection of Third-Party Online Drug Trading Platforms
The National Medical Products Administration (NMPA) has issued a new set of “Guidelines for the...
Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate
The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical...
China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training
The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...
China’s CDE Releases Guidelines for CGT Clinical Trials Communication
The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...
China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste
The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...
China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities
The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...
China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP
The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...